Dimensional Fund Advisors Ltd. : Form 8.3 – DS SMITH PLC
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors…
Dimensional Fund Advisors Ltd. : Form 8.3 – SPIRENT COMMUNICATIONS PLC
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors…
SHARE BUYBACK TRANSACTIONS
COMPANY ANNOUNCEMENT no. 68 - 16 September 2024 On 9 February 2024, DFDS A/S (“DFDS”) announced the initiation of a share buyback programme to be executed in accordance with EU…
AKTIETILBAGEKØBSHANDLER
SELSKABSMEDDELELSE nr. 68 - 16. september 2024 Den 9. februar 2024 meddelte DFDS A/S (“DFDS”) iværksættelsen af et aktietilbage-købsprogram til gennemførsel i henhold til EUs markedsmisbrugsforordning, EU forordning nr. 596/2014…
iTeos annonce un taux de réponse objective cliniquement significatif observé à chaque dose lors de l’analyse intermédiaire de suivi de l’étude GALAXIES Lung-201 portant sur l’association belrestotug + dostarlimab dans le traitement de première ligne des patients atteints d’un cancer du poumon non à petites cellules et présentant un taux de PD-L1 élevé
- Un taux de réponse objective (TRO) cliniquement significatif de 63,3–76,7 % a été observé avec l’association belrestotug + dostarlimab, avec un TRO confirmé (TROc) d'environ 60 % pour chaque…
iTeos gibt klinisch bedeutsame objektive Ansprechrate bekannt – Beobachtung bei jeder Dosis in der Zwischenanalyse des Nachbeobachtungszeitraums der GALAXIES Lung-201-Studie zu Belrestotug + Dostarlimab bei Patienten mit nicht-kleinzelligem Lungenkrebs mit hoher PD-L1-Expression in der Erstlinienbehandlung
- Klinisch bedeutsame objektive Ansprechrate (Objective Response Rate, ORR) von 63,3–76,7 % bei der Kombination von Belrestotug + Dostarlimab, mit einer bestätigten ORR (confirmed ORR, cORR) von ca. 60 %…
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12),…
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit,…
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset…
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohortResponses with Rina-S were observed…